Reolysin: Additional Phase II data

Oncolytics reported data from 21 evaluable chemotherapy-naïve patients with metastatic or recurrent SCC of the lung in the 2-stage, open-label, U.S. Phase II REO 021 trial showing that IV Reolysin plus paclitaxel and carboplatin met the primary endpoint of an ORR of >=35%. Specifically, Reolysin plus paclitaxel and carboplatin led to an ORR of 42.8%, including 9 partial responses (PR) plus 9 cases of stable disease, which the company had previously reported (see BioCentury, Feb. 11). Patients received IV Reolysin on days 1-5 plus paclitaxel and carboplatin on day 1 of a 21-day cycle. Based on the data, Oncolytics said it plans to conduct additional studies in the indication, but could not be reached for details. ...